p73 has recently been identi®ed as a structural and functional homolog of the tumor suppressor protein p53. Overexpression of p53 activates transcription of p53 eector genes, causes growth inhibition and induced apoptosis. We describe here the eects of a tumor-derived truncated transcript of p73a (p73Dexon2) on p53 function and on cell death. This transcript, which lacks the acidic N-terminus corresponding to the transactivation domain of p53, was initially detected in a neuroblastoma cell line. Overexpression of p73Dexon2 partially protects lymphoblastoid cells against apoptosis induced by anti-Fas antibody or cisplatin. By cotransfecting p73Dexon2 with wild-type p53 in the p53 null line Saos 2, we found that this truncated transcript reduces the ability of wild-type p53 to promote apoptosis. This anti-apoptotic eect was also observed when p73Dexon2 was co-transfected with fulllength p73 (p73a). This was further substantiated by suppression of p53 transactivation of the eector gene p21/Waf1 in p73Dexon2 transfected cells and by inhibition of expression of a reporter gene under the control of the p53 promoter. Thus, this truncated form of p73 can act as a dominant-negative agent towards transactivation by p53 and p73a, highlighting the potential implications of these ®ndings for p53 signaling pathway. Furthermore, we demonstrate the existence of a p73Dexon2 transcript in a very signi®cant proportion (46%) of breast cancer cell lines. However, a large spectrum of normal and malignant
Introduction
Exposure of mammalian cells to DNA damaging agents leads to the stabilization and activation of the tumor suppressor p53 which in turn causes the induction of a series of p53 eector genes (El-Deiry et al., 1993; Kastan et al., 1991) . As a consequence, cell cycle arrest may occur due to activation of the G1/S checkpoint or the cells may undergo apoptosis (ElDeiry et al., 1993; Polyak et al., 1997) . These activities have been linked to the ability of p53 to bind to speci®c DNA sequences and activate transcription. Loss of p53 function by mutation (Levine et al., 1995) , or by interaction with viral proteins (Bargonetti et al., 1992; Debbas and White, 1993) , leads to deregulated growth, genome instability and resistance to apoptosis.
Attempts to ®nd p53-related genes by low stringency hybridization and by degenerate PCR have repeatedly failed. Fortuitously, Kaghad et al. (1997) isolated a cDNA encoding p73 in a hybridization screen of a COS cell cDNA library using degenerative oligonucleotide primers for a dierent gene. This in turn led to the isolation of two splice variants of p73, p73a (full-length form) and p73b (spliced out exon 13), that dier in the C-terminus of the molecule. Similar to p53, p73 can activate transcription of p21, a gene involved in cell growth arrest, and can induce apoptosis when overexpressed (Jost et al., 1997) . The p73 gene maps to the short arm of chromosome 1 in a region (1p36.33) that is frequently deleted in neuroblastomas (Kaghad et al., 1997) , suggesting that it may play a role in the development of these tumors. However, infrequent or absent mutations in the p73 gene in lung cancer (Mai et al., 1998a; Nomoto et al., 1998) , prostate cancer , oligodendrogliomas (Mai et al., 1998b; Nomoto et al., 1998) , and colorectal carcinomas (Sunahara et al., 1998) , suggest that p73 does not function as a tumor suppressor, at least in the classical sense.
A number of other p53-related genes have also been described recently, including p51/KET (Osada et al., 1998; Schmale and Bamberger, 1997) now called p63 (Yang et al., 1998) , p53RE, p53 response element binding protein (Zheng et al., 1998) and p53CP, a putative p53 competing protein for which the gene remains uncloned. More recently, two new splice variants of p73, g (splicing out exon 11) and d (splicing out exons 11, 12, 13) have been identi®ed in both normal cells and dierent tumor cell lines (De Laurenzi et al., 1998) . These spliced variants of p73 may play a distinct role in cells of dierent lineages or at dierent dierentiation stages within the same lineage. Various p73 isoforms are capable of interacting with themselves and p53 in a yeast two-hybrid system, and therefore may also modulate the function of p53 (De Laurenzi et al., 1998) .
Like p53, p73 has multiple, unique and functional domains. These include the acidic N-terminus, corresponding to the transactivation domain of p53, the sequence speci®c DNA binding domain, and the oligomerization domain. Importantly, one spliced variant of p73 (p73Dexon2) has been observed in a neuroblastoma cell line (Kaghad et al., 1997) but not in normal cells. This splice variant lacks most of the N-terminal domain corresponding to the transactivation domain of p53. Casciano et al. (1999) have reported major dierences in the expression of p73 and p73Dexon2 in independent areas of a synchronous multifocal neuroblastoma, showing dierent levels of cell death. The dierential expression of p73 isoforms in the biologically distinct tumor areas may indicate that interaction of several p73 isoforms between themselves and with p53 might have profound eects in the control of programmed cell death. More recently, characterization of p73 isoform expression in developing brain revealed transcripts encoding p73 proteins that lacked amino-terminal transactivation domain (p73Dexon2) and importantly this transcript appeared to be the predominant p73 gene product in adults and during embryogenesis.
Here we have designed appropriate in vitro assays to assign a speci®c function to the p73Dexon2 variant. We provide evidence that this splice variant (p73Dexon2) acts as a dominant-negative agent towards transactivation by p53 and p73a. This transcript also interferes with apoptotic functions of p53, highlighting the importance of these ®ndings for p53 signaling pathways. In addition, we demonstrate the existence of this transcript in a signi®cant percentage of breast cancer cell lines, thus providing evidence for a potential role for p73Dexon2 in tumorigenesis.
Results

Cloning and expression of p73Dexon2
In describing the gene encoding p73, Kaghad et al. (1997) observed a second transcript which was present at 10 per cent abundance in a neuroblastoma cell line, SK-N-SH. This transcript represents an inframe splice variant lacking exon 2 with an ATC at nucleotides 255 ± 257 (SPTREMBL; 015350/015351). The protein predicted from this transcript would have a deletion of most of the N-terminal transactivation domain. This spliced variant, p73Dexon2, was cloned into an expression vector, pMEP4, prior to transfection into a lymphoblastoid cell line (LCL), C3ABR. p73Dexon2 expression was induced with CdCl 2 (5 mM), and protein levels determined by immunoblotting and immunoprecipitation using antibodies prepared against a region of p73 (aa 451 ± 636). Immunoblotting of the total cell lysates with anti-p73 antibody revealed the presence of a single protein band corresponding in size to p73Dexon2 in C3ABR cells transfected with p73Dexon2 and induced with CdCl 2 (Figure 1a ). This protein was not detected in vector only transfected cells. Immunoprecipitation with p73 antibody followed by immunoblotting with the same antibody again showed a prominent band corresponding to p73Dex-on2. Endogenous p73, which is present at low levels in nuclei, was not detected because total lysates were employed in these experiments. Immunoblotting and immunoprecipitation with anti-Flag antibody produced the same pattern of expression (results not shown).
Inhibition of apoptosis by p73Dexon2 expression
The dramatic increase in p73Dexon2 in transfected cells, upon induction with CdCl 2 suggested that this might be a useful system to study the eect on apoptosis and p53 function. Previous studies have shown that apoptosis can be readily triggered in LCLs by treatment with various chemotherapeutic agents such as cisplatin, actinomycin D and adriamycin (Allday et al., 1993; Fritsche et al., 1993) . LCLs respond to these damaging agents with a rapid commitment to apoptosis. It is widely accepted that the pathway of DNA-damage-induced apoptosis is largely mediated by p53. Prior to cell death there is a substantial accumulation of p53 protein, and increases in the expression of p53 responsive genes p21/Waf1 and MDM2 are consistent with the p53 being transcriptionally active (Lane, 1994) . Four representative lines of transfected C3ABR cells, one containing the empty pMEP4 vector, one expressing p73Dexon2, one expressing wild-type (wt) p53 and one expressing a mutant form of p53 were established and treated with CdCl 2 (5 mM) to induce ectopic expression of these cDNAs. As in the case of p73Dexon2, overexpression of p53 was monitored by immunoblotting with antip53 antibodies. There was a marked induction of expression of exogenous p53 in wild-type and mutant p53 transfected C3ABR cells within 8 h of induction with CdCl 2 (Figure 1b ). In addition, CdCl 2 treatment induced a modest but signi®cant increase in the endogenous p53. The exogenous p53 migrates ahead of the wt p53 because of the nature of the construct (Vousden et al., 1993) . The percentage apoptosis at indicated times after treatment with cisplatin was determined by¯uorescence microscopy. Untreated cells stained with Hoechest dye and viewed under ā uorescence microscope appeared as smooth, intact spheres (Khanna et al., 1996) , whereas the cisplatintreated cells showed chromatin condensation and nuclear morphology characteristic of apoptosis (Khanna et al., 1996) . A number of normal and apoptotic cells were scored from a series of indepen-dent experiments to determine the percentage of cells that exhibited apoptotic features. When C3ABR cells (transfected with vector only) were exposed to cisplatin (10 mg/ml) there was a substantial increase in apoptosis reaching 70% by 35 h post-treatment ( Figure 2a ). This corresponds well with the rate of apoptosis in untransfected C3ABR cells treated with cisplatin (results not shown). Overexpression of wt p53 (BL2) with a CdCl 2 -inducible EBV-construct (as monitored in Figure 1b ) enhanced the rate and extent of apoptosis ( Figure 2a ). On the other hand, overexpression of mutant p53 (BL41), did not alter the rate and extent of apoptosis. This is consistent with previously published results where LCLs transfected with this mutant (BL41) retain normal sensitivity to cisplatin. (Allday et al., 1995) . When p73Dexon2 transfected cells, induced to express protein, were exposed to cisplatin the extent of apoptosis was signi®cantly reduced at all time points up to 35 h ( Figure 2a ). To test the universality of this inhibition against apoptosis by p73Dexon2, we exposed cells to anti-Fas antibody to determine the extent of apoptosis in dierent transfected cell lines. As observed with cisplatin, overexpression of wt p53 in C3ABR cells resulted in increased responsiveness towards anti-Fas mediated apoptosis (Figure 2b ). This is consistent with recent ®ndings that both DNA damage of cells containing wild-type p53 and transfection of wt p53 into p53-null cells causes induction of the CD95 receptor (Friesen et al., 1996; MuÈ ller et al., 1998) , resulting in ecient induction of Fas-mediated apoptosis in dierent cell types (Miyake et al., 1998; MuÈ ller et al., 1997; Tamura et al., 1995) . As observed with cisplatin, p73Dexon2 expressing C3ABR cells were both signi®cantly protected against anti-Fas-induced apoptosis ( Figure 2b ). p53 has been implicated in cell death induced by cisplatin and anti-Fas (Allday et al., 1995; Friesen et al., 1996; MuÈ ller et al., 1997 MuÈ ller et al., , 1998 . The ®nding that p73Dexon2 protects cells from apoptotic cell death raised the possibility that this protection may involve an inhibition of p53 apoptotic activity. To test this possibility we co-transfected Saos 2 cells, which harbor a homozygous deletion at the p53 gene locus and fail to produce p53 protein, with a wt p53 expression construct alone or together with plasmids encoding either full-length p73a or p73Dexon2. Sixty hours posttransfection cells were harvested and transfected cells were identi®ed on the basis of high p53¯uorescence. The extent of apoptosis for each transfected population (5000 cells) was determined by¯ow cytometric analysis (Haupt et al., 1996) . Transfection of Saos-2 cells with either p53 alone or together with wt p73a induced similar levels of apoptosis in Saos-2 cells (31 and 28% respectively; Figure 3a ). Presumably, this high level of apoptosis by p53 alone masks additional eect by p73a. However, co-expression of p73Dexon2 together with p53 resulted in a signi®cant reduction (by 60%) in the extent of apoptosis (Figure 3a ). The reduction in p53 apoptotic activity was not due to a reduction in its expression, on the contrary p53 expression was consistently increased upon co-transfection with p73Dexon2 (data not shown). Thus, co-expression of p73Dexon2 can interfere eciently with the apoptotic activity of p53 and this dominant negative eect was speci®c to p73Dexon2 as full-length p73a failed to demonstrate this eect.
If p73Dexon2 can interfere with p53 activities it is likely that it may also interfere with its own counterpart, wt p73a. This assumption was tested in Saos-2 cells by co-transfecting wt p73a together p73Dexon2, and the transfected cells were identi®ed by co-expressing Figure 1 Ectopic expression of p73Dexon2, wild-type (wt) and mutant p53 (mut) in a lymphoblastoid cell line. (a) A lymphoblastoid cell line (C3ABR) was transfected with either vector alone (V) or p73Dexon2 c-DNA cloned into pMEP4 by using the Lipofectin reagent (Life Technologies) according to the manufacturer's instructions. Stably transfected cells were induced with 5 mM CdCl 2 for 8 h. Total cell extracts from transfected C3ABR were immunoblotted (20 mg extract) and immunoprecipitated (50 mg extract) followed by immunoblotting with polyclonal anti-p73 antibody. (b) C3ABR cells were transfected with either vector alone, wild-type or mutant p53 cDNA cloned into pMEP4. Cells were treated with CdCl 2 for 8 h and nuclear extracts (20 mg) were immunoblotted with anti-p53 antibody (PAb 1801) a GFP expression plasmid together with p73 plasmids. As shown in Figure 3b , wt p73a alone induced 10% apoptosis, while p73Dexon2 induced only 1.3%. Coexpression of p73Dexon2 together wt p73a reduced the extent of apoptosis by 50% compared to that in p73a alone. Although the extent of apoptosis was low, the reduction was consistent over several independent experiments. Thus, as for p53, p73Dexon2 can interfere with the apoptotic function of its wild-type counterpart (Figure 3b ). It should be noted that the extent of apoptosis induced by wt p73a was signi®cantly lower than that induced by wt p53 (10% versus 30%, respectively). This dierence re¯ects, by and large, the dierent methods used for detecting the transfected cells. The p53 transfectants were identi®ed by virtue of their high p53 expression. On the other hand, the p73 transfectants were identi®ed according to GFP expression in co-transfectants. In cells transfected with GFP and p73a there is a growth selection for cells expressing GFP alone, and counter selection against GFP-p73 coexpressors. By 60 h post-transfection, there is an enrichment of cells expressing GFP alone. Therefore, the extent to which p73a induces apoptosis is underestimated using this approach. Nevertheless, the relative interference of p73Dexon2 with the apoptotic ability of wt p73a could be measured. The eects were consistent in several experiments and p73Dexon2 interfered with the apoptotic function of its wild-type counterpart.
p73Dexon2 interferes with the transcriptional activity of p53
Previous results have shown that overproduction of full-length p73 activates transcription from p53-responsive promoters and induces apoptosis (Kaghad et al., 1997; Jost et al., 1997) . Since p73Dexon2 was shown to markedly inhibit apoptosis resulting from p53 expression in Saos-2 cells, it seemed likely that this truncated form of p73 was competing for p53-responsive promoters. To address this we measured the induction of the p53 eector gene p21/WAF1, a cyclin kinase inhibitor which is induced in response to DNA damage and other agents (El-Deiry et al., 1993) . In response to CdCl 2 treatment or radiation exposure there was an increase in p21 protein in C3ABR cells transfected with empty vector (Figure 4 , middle panel) and the extent of induction was greater in irradiated cells. A combination of radiation and CdCl 2 did not lead to induction greater than radiation alone. However, in p73Dexon2 transfection cells induction of expression of p73Dexon2 (Figure 4, top panel) by CdCl 2 treatment inhibited the induction of p21, and in cells treated with both radiation and CdCl 2 , the radiation-induced increase of p21 levels was completely abrogated (Figure 4, middle panel) . The eect was not due to interference with the stabilization of p53, which occurred to the same extent in vector and p73Dexon2 transfected cells (results not shown).
As an additional approach to demonstrating that p73Dexon2 was suppressing the transactivation activity of p53, we employed a CAT reporter assay. Empty vector and p73Dexon2 stably transfected C3ABR were transiently transfected with p53 reporter plasmid PG13, containing 13 copies of the ribosomal gene cluster p53 consensus binding site (Kern et al., 1992) , or mutated binding site, MG15 (Kern et al., 1992) , and transactivation, due to the presence of endogenous p53, and family members in these cells was determined by measuring CAT activity. The transactivation was visualized by employing a thin layer chromatography (TLC)-based assay (Gorman et al., 1982) . Vector only transfected cells had a high level of CAT activity, but expression of p73Dexon2 in the transfected cells suppressed this activity approximately 3 ± 4-fold (Figure 5a) , providing further support for interference with the transactivation activity of p53 and family members by the truncated protein. No activity was observed with plasmid with a mutated binding site. Similar results were obtained with Saos-2 cells, wherein coexpression of p73Dexon2 with p53 completely abolished the transactivation of p53 at an equal ratio of transfection (Figure 5b, left panel) . Similarly, coexpression of p73Dexon2 with p73a at equal ratios of transfection markedly reduced transactivation by p73a, and the activity was completely lost when the ratio was increased to 1 : 5 (Figure 5b, right panel) .
Demonstration of p73Dexon2 transcript in breast cancer cell lines
Recently, Zaika et al. (1999) reported overexpression of wild-type p73 in breast cancer cell lines. Tumors and cell lines with p73 overexpression tended to exhibit a complex pro®le of C-terminal p73 variants, whereas normal and transformed tissues with low level of p73 mRNA predominantly expressed p73a. These carboxy terminal p73 isoforms seem to have very dierent biological eects (De Laurenzi et al., 1998) but none of them have been shown to have a dominant negative eect. It is possible that the dominant negative p73 variants may be expressed, and thus it is important to Figure 4 p73Dexon2 suppresses the induction of the p53 eector gene WAF1/p21 in response to DNA damage. C3ABR cells transfected with either vector alone or p73Dexon2 were uninduced (7) or induced (+) with CdCl 2 for 8 h followed by either mockirradiation (7) or irradiation (+) with 6 Gy and harvested 2 h later. Nuclear lysates were prepared and immunoblotted with either anti-p73 (top), anti-p21 (middle) or PCNA (bottom) as a loading control Figure 5 p73Dexon2 interferes with transactivation by p53 and p73a using a p53-responsive promoter. (a) Empty vector or p73Dexon2 stably transfected cells were transiently transfected with p53 reporter plasmid PG13 CAT in duplicate or MG15 CAT. CAT activity was measured by a thin layer chromatography based assay. (b) Saos 2 cells were co-transfected with PG13 CAT together with p53 and p73Dexon2 or p73a and p73Dexon2 at 1 : 1 and 1 : 5 ratios, as indicated. CAT activity was assayed by a TLC-based assay Truncated p73 transcript inhibits p53 functions I Fillippovich et al determine whether they occur in a tumor speci®c manner. To assess the existence of N-terminal dominant negative variant (p73Dexon2), a number of breast cancer cell lines (Table 1) were screened for the existence of this transcript by RT ± PCR ampli®cation followed by hybridization. In accordance with a previous report (Zaika et al., 1999) 10 of the 13 breast cancer cell lines tested here overexpressed wild-type (Table 1 ), and Figure 6 shows results with some of the representative lines. A 277 bp fragment of expected size for the full-length p73 transcript was easily detected in these lines (Figure 6 ). An additional fragment of 172 bp corresponding to the p73Dexon2 variant (Figure 6 ), was detected in 6 of the 9 cell lines (=66%) which overexpressed p73 (Table 1) . It is important to note that the ratio of the wild-type to truncated transcript diered greatly among individual cell lines. Thus, this dominant negative variant of p73 exists and it will be important to determine whether it occurs only in a tumor-speci®c manner.
Discussion
p73 protein is related to p53 through three functional domains; the transactivation, DNA-binding and tetramerization domains (Kaghad et al., 1997) . While overexpression of p73 leads to activation of reporter genes containing a p53 responsive sequence, growth suppression and apoptosis, its physiological signi®-cance remains unknown. It is well established that p53 is stabilized and activated by a series of DNA damaging agents (Kastan et al., 1991) , which results in cell cycle delay and/or apoptosis. On the other hand, p73 is regulated dierently by various DNA damaging agents. P73 protein is stabilized after treatment of cells with cisplatin (Gong et al., 1999) , but not with girradiation or ultraviolet light. Conversely, p73 is tyrosine phosphorylated with g-irradiation (Yuan et al., 1999) but not with cisplatin. Nonetheless, activation of p73 requires functional c-Abl as neither stabilization nor phosphorylation occurs in c-Ablde®cient cells (Gong et al., 1999; Yuan et al., 1999) .
In this study we have taken a dierent approach designed to understand the relationship between p73 and p53. Similar to p53, p73a is a potent inducer of cell death and shows strong transactivation ability in a reporter system using p53 response elements. Conversely, overexpression of a splice variant of p73a, p73Dexon2, which lacks the putative N-terminal transactivation domain, had the opposite eect to overexpression of the full-length protein. In short, this truncated form of p73 reduced apoptosis induced by anti-Fas antibody and cisplatin. Furthermore, when co-expressed with p53 in saos2 cells, lacking p53, it led to a very signi®cant reduction in apoptosis, induced by p53, whereas full-length p73 caused apoptosis. The anti-apoptotic eect of p73Dexon2 in Saos2 cells suggested that it was interfering with the transcriptional function of p53. This was con®rmed by transfection studies showing that p73Dexon2 inhibited the expression of a CAT reporter gene under the control of a p53 promoter and reduced the induction of the p53 eector gene p21/Waf1. This observation indicates that p73Dexon2 may also inhibit other functions of p53, such as activation of cell cycle checkpoints, as p21 is involved primarily in the activation of cell cycle checkpoints rather than apoptotic pathways. These data with the p73 variant contrast with those observed with full-length p73, which when overproduced, activates transcription from p53-responsive promoters and induces apoptosis (Kaghad et al., 1997; Jost et al., 1997; Marin et al., 1998) . Pertinent to these observations are the parallels that exist between p73 and another member of the p53 family, p63. This gene encodes multiple isotypes with dierent capacities to transactivate p53 reporter genes and to cause apoptosis (Yang et al., 1998) . Of particular signi®cance is the observation that the predominant isotypes (DNp63) expressed in many epithelial tissues lack the sequence corresponding to the transactivation domain in p53. In this respect they resemble p73Dexon2, which also lacks the putative transactivation domain. Expression of DNp63 isotypes Figure 6 Identi®cation of p73Dexon2 transcript in breast cancer cell lines. The PCR products obtained after ampli®cation with amplimers (see methods) were blotted on to nylon membrane and hybridized with a probe speci®c to 5' end of p73 cDNA (see methods). Note 277 bp product corresponds to expected size for wt p73 and 172 bp correspond to the exon 2 deleted variant (p73Dexon2). The GAPDH panel serves as a control for loading produced a dose-dependent inhibition of p53 transactivation in Saos 2 cells. Because of the high degree of homology in the DNA-binding domain regions of p53, p73 and p63, it seemed likely that DNp63 isotopes were competing for p53 target sites. Electrophoretic mobility shift assays demonstrated speci®city of DNp63 for p53-binding (Yang et al., 1998) . These results suggest a common mechanism of interference for DNp63 and p73Dexon2 in competing with p53 for p53 target sites. Another mechanism by which p73Dexon2 could aect transactivation by p53 is via direct protein ± protein interaction, presumably through their oligomerization domains. We tested the potential for such interaction by co-immunoprecipitation experiment but failed to reveal an interaction with p53 (results not shown). Thus, while we demonstrated that p73Dexon2 can interfere with p53 controlled gene expression we were unable to provide evidence of a complex between the two molecules. Di Como et al. (1999) also failed to demonstrate interaction between p73a and wild-type p53 in transfected cells, but they found that p73a coimmunoprecipitates with two hot-spot mutants of p53 (R175H and R248W). Upon co-transfection with p73a both of these mutants reduce the transcriptional activity of p73a, correlating with the reduced ability of p73a to cause apoptosis in the presence of p53 mutants. Yang et al. (1998) demonstrated interaction between p63 isotypes, but failed to reveal interaction of any of these isotypes with p53, however the isotypes were capable of interfering with the transactivation function of p53 due to direct competition with p53 for binding to p53 sites. Similarly, p73Dexon2 has recently been shown to have speci®city for p53 binding sites . More recently, direct interaction between p73Dexon2 and p53 has also been demonstrated using a glutathione S-transferase (GST)-linked p73Dexon2 (Pozniak et al., 2000) . Furthermore, using the yeast two-hybrid system we were able to demonstrate that p73Dexon2, interacts weakly with p53 (data not shown). Taken together, these results suggest that p73Dexon2 might antagonise p53 activity by heterooligomerization and direct competition for p53 targets.
The location of p73 on chromosome 1p36, a region frequently deleted in dierent tumor types, together with its ability to cause apoptosis, provide persuasive evidence for a role for p73 as a tumor suppressor gene (Kaghad et al., 1997; Jost et al., 1997) . However, mutation analysis on the p73 gene in a variety of tumors does not support this proposition. The data described here, outlining an anti-apoptotic role for a splice variant of p73, together with similar data for p63, point to a more complex picture of gene control. What is the physiological signi®cance of p73Dexon2? In the analysis of p73 transcripts in dierent tumor cell lines, Kaghad et al. (1997) demonstrated that 10 per cent of the transcripts in a neuroblastoma cell line, SK-N-SH, contained a deletion in exon 2. While this truncated transcript is less abundant in these cells it may nevertheless represent part of a novel mechanism to circumvent the growth inhibiting eects of wild-type p53 in a sub-group of tumors.
More recently Casciano et al. (1999) have reported dierential expression pattern of various p73 isoforms in independent areas of a synchronous multifocal neuroblastoma. Poorly dierentiating neuroblastoma only expressed p73Dexon2 splice variant, whereas undierentiated neuroblastoma expressed p73a and b as well as p73Dexon2 splice variants. The presence of dierent splicing variants in the biologically distinct tumor areas might indicate that the interaction of several p73 isoforms between themselves and with p53 might have profound eects in the control of programmed cell death. In accord with our results, wt p73 overexpression has been observed in many dierent cancers including breast (Zaika et al., 1999) , prostate and lung cancer (Mai et al., 1998a) but not in matched normal counterparts. The data presented herein provides an additional and convincing evidence for the existence of a dominant negative variant of p73, p73Dexon2, in a very signi®cant proportion (66%) of the breast cancer cell lines that overexpress p73. However, the biological signi®cance of expression of p73Dexon2 in tumor cells is unclear at present. The full-length p73a gene itself behaves more like an oncogene, as it is commonly overexpressed in tumors. It is thus hard to argue that p73Dexon2 acts as an oncogene to antagonize p73a. It is also dicult to imagine that overexpression of p73Dexon2 acts to inhibit p53 in breast cancer lines, because in some of the breast cancer lines where p73Dexon2 was overexpressed, the p53 gene was mutated.
Interestingly, while this manuscript was under preparation, Pozniak et al. (2000) documented an antiapoptotic role for the p73Dexon2 during developmental neuronal death. p73 is primarily present as a truncated isoform (p73Dexon2) in developing neurons, and increased expression of this truncated isoform rescues the neurons from apoptosis induced by p53 overexpression or by nerve growth factor withdrawal. Our ®ndings concur with the above report that p73Dexon2 is antiapoptotic and serves to counteract the pro-apoptotic functions of p53. However, with regards to relevance of p73Dexon2 overexpression in tumors, a large spectrum of normal and malignant tissues needs to be surveyed to determine whether this dominant negative transcript exists in a tumor speci®c manner. Thus, it is likely that several splice variants of p73 may participate, in dierent ways, in a complex network that regulates cell growth, death and dierentiation.
Materials and methods
Cloning of p73Dexon2, a splice variant of p73
We designed primers to amplify a product (lacking exon 2 of p73) from nucleotides 255 ± 2021 with¯anking KpnI and HindIII sites for cloning into the EBV-based expression vector pMEP4. A Flag ± Kozak oligonucleotide¯anked by KpnI sites was inserted into this construct after digestion with KpnI to produce p73Dexon2. DNA sequence analysis was carried out to con®rm the integrity of the inserted material. For cloning into pcDNA 3.1, the same primer set,¯anked by BamHI and XhoI sites, was used to amplify and clone p73Dexon2. The Flag ± Kozak sequence was subsequently cloned inframe into this construct by digestion of a KpnI site upstream from the BamHI site in the vector. In order to produce a fragment of p73 suitable for speci®c antibody production, the ampli®ed fragment¯anked by BamHI ± XhoI sites was digested with SmaI and the resulting fragment (560 bp) was cloned into pGEX-5X-2. The GST-fusion protein was prepared in E. coli and used to immunize rabbits.
Plasmids
Conditional Wt (BL2) and mutant (BL41) p53 expression constructs were a gift of PJ Farrell, pCEP-SN (wt p53), PG13 CAT and MG15 CAT were provided by Bert Vogelstein; human p53 expression vector pCMV-Neo-Bam-p53; GFP expression vector pEGFP were from Clontech. The construction of p73a in pcDNA 3.1 was described previously (Kaghad et al., 1997) .
Antibodies
Polyclonal and monoclonal antibodies against p73 were generated by standard techniques. Rabbits or Balb/C mice were immunized with glutathione S-transferase (GST)-p73 (aa 451 to 636) fusion protein for polyclonal and monoclonal antibody preparation respectively. This antibody was designed so as to minimise the likelihood of generating antibodies that would cross react with p53. The antibodies were screened based on their ability to detect the original immunogen by Western blotting and immunoprecipitation analysis. Monoclonal anti-p21 (OP 64) and anti-PCNA antibody were obtained from Oncogene Science. Anti-human p53 monoclonal antibodies PAb1801 and DO1 were a gift from David Lane.
Transfections
A lymphoblastoid cell line, C3ABR established from a normal individual was transfected with p73Dexon2 cloned into pMEP4, wild-type p53, mutant p53, and pMEP4 alone. Transfections were carried out as previously described (Zhang et al., 1997) . Selection was carried out with hygromycin B (Boehringer Mannheim) at 0.2 mg/ml and stably transfected cells are usually obtained at 3 ± 4 weeks after transfection. Anti-Fas and cisplatin-induced cell death in transfected cells, was analysed at the indicated time intervals by morphological examination (Khanna et al., 1996) .
Saos-2, p53-null osteosarcoma cells, were transiently transfected with pcDNA-p73Dexon2 and other expression constructs, as indicated, by the calcium phosphate method. The DNA precipitates were left on the cells for 6 h. The plasmid used and the exact amount of DNA is indicated in the corresponding ®gure legends. Whenever needed, an empty vector was used to maintain a constant amount of DNA in each transfection mix. Cells were subsequently shocked for 1 min with medium containing 10% glycerol. Twenty-four hours after the removal of the precipitates the cells were harvested for CAT assays as previously described (Gorman et al., 1982) . For the apoptotic assay, cells were collected 60 h post-transfection. Floating and adherent cells were combined, ®xed in methanol and stained for p53 using a mixture of antip53 antibodies, DO-1 and PAb1801, followed by an FITCconjugated secondary antibody. Samples were analysed in a cell sorter (FACS Calibur) using the CellQuest software (Becton Dickinson). The apoptotic fraction of the transfected cells was determined by quantitating the number of cells possessing a sub-G1 DNA content as previously described (Haupt et al., 1995 (Haupt et al., , 1996 . The eect of wt p73 and p73Dexon2 on cell death was determined by tagging the transfected cells with GFP. Cells were co-transfected with p73 expression plasmids together with a GFP expression plasmid. Cells were collected and ®xed as described above and then subjected to¯ow cytometric analysis.
Detection of p73Dexon2 transcript in breast cancer cell lines
The following breast carcinoma lines were included in the study: BT 20, DU 4475, MCF-7, MDA-MB-231, MDA-MB-453, SK-Br-3, T47D, UACC-893, ZR-75-10 and ZR-75-30 (ATCC, Rockville, MD, USA), MA11 (a gift of Dr Philip Rye, Oslo, Norway), KPL-1 (a gift of Dr Junichi Kurebayashi, Suzuki, Japan), and MDA-MB-435 and MDA-MB-468 (a gift of Dr Janet Price, MD Anderson Cancer Center, Houston, TX, USA). All cell cultures were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS) with the following exceptions: KPL-1 was maintained in DMEM with 5% FCS, MA11 in 1 : 1 Ham's F12: RPMI-1640 with 10% FCS. The HBL100, SV-40 transformed breast epithelial line derived from a nursing mother, was used as a control. Total RNA was isolated using the Trizol reagent and was reverse transcribed (RT) using Superscript reverse transcriptase (Gibco ± BRL). PCR was performed using the forward primer 5'-GGACGGACGCCGATGCC-3' and the reverse primer 5'-GGTCCATGGTGCTGCTCAGC-3' for 30 cycles (948/648/728 for 30 each) and the wild-type and Dexon2 variants were identi®ed on the basis of their expected size and by hybridization. For hybridization the PCR products were blotted onto a nylon membrane and hybridized with a 5' end p73 probe obtained by restriction digestion of p73 cDNA cloned in pcDNA3.1 vector (Kaghad et al., 1997) with BPU1102 and XhoI.
